Ares Management
ARES
$133.98
+0.19%
Ares Management is one of the world's largest alternative asset managers, overseeing $671.3 billion in total assets under management (including $409.9 billion in fee-earning AUM) across four segments: credit strategies ($440.5 billion), private equity ($24.5 billion), real estate/real assets ($151.2 billion), and other alternatives ($55.1 billion), serving a client base that is roughly 80% institutional and 20% high-net-worth across more than 35 offices in over 15 countries. Its identity is anchored in credit — it is arguably the preeminent scaled private credit franchise among listed alternatives managers — which makes it both a structural beneficiary of the bank-disintermediation theme and the most direct public-market proxy for sentiment toward private credit. The current investor debate is dominated by that double-edged exposure: headlines through 2026 have centered on private credit stress (Blue Owl capping redemptions in April, a $1.4 billion fund liquidation in February that triggered a sector-wide risk-off move), and Ares shares have de-rated sharply year-to-date even as the firm continues to raise and deploy capital. The narrative now hinges on whether fee-related earnings growth and fundraising momentum can outrun credit-quality fears and a compressed valuation multiple, with the stock's violent August rally and subsequent fade capturing that tug-of-war.…
ARES
Ares Management
$133.98
Related headlines
Investment Opinion: Should I buy ARES Today?
Rating: Hold with a constructive tilt. The core thesis is that ARES is a scaled, fee-driven private credit franchise trading near the low end of its multi-year valuation band (5.43x PS and 8.22x P/B versus historical PS of roughly 10.2x–36.1x), with a 5.0% dividend yield and an analyst consensus of "buy" (13 Buy, 7 Hold, 0 Sell) anchored by an average target of $146.50, implying +13.6% upside from $128.93. The tension is that reported fundamentals are deteriorating faster than the valuation is cheapening: revenue fell 8.69% YoY to $1.514 billion in Q3 2026 and net income collapsed to $85.3 million from $288.9 million, so the case rests on forward EPS of $9.36 materializing against trailing EPS of just $0.015.
Supporting evidence is genuinely two-sided. On the positive side, the forward PE of 18.48x is undemanding in absolute terms and dramatically below the meaningless 82.46x trailing multiple; management fees of $1.039 billion anchor the revenue base within $409.9 billion of fee-earning AUM; gross margin improved to 79.49% from 60.19% a year earlier; and the analyst low target of $128.00 sits essentially at the current price, implying the Street sees no downside from here. On the negative side, interest expense of $250.7 million consumed roughly 69% of Q3 operating income of $365.1 million, debt-to-equity is 3.49x, the 3.33x payout ratio means the 5.0% yield is not covered by current earnings, TTM free cash flow of $836.1 million is only a ~1.6% FCF yield on the ~$52.5 billion market cap, and EPS has slid sequentially from $0.52 to $0.49 to $0.26. The stock is down 22.49% YTD with -33.11% relative strength versus the S&P 500, so the market has already priced substantial pessimism.
The biggest risks that could invalidate the thesis are: (1) a renewed private credit shock — another redemption gate or fund liquidation like Blue Owl's April cap or February's $1.4 billion liquidation — given credit strategies are $440.5 billion of $671.3 billion AUM; (2) failure of the $9.36 forward EPS estimate to materialize, which would expose the 18.48x forward PE as a value trap; and (3) dividend coverage stress if realizations stay weak, since Q2 dividends of $513.8 million exceeded that quarter's operating cash flow. This Hold would upgrade to Buy if fee-related earnings growth resumes and the stock breaks above the August high of $149.45, or if forward EPS estimates hold while the multiple stays below 20x; it would downgrade to Sell if revenue growth stays negative for another quarter, EPS falls below $0.20, or a new sector credit event pushes the stock below the October low of $112.27. On balance the stock is modestly undervalued on forward earnings but fairly-to-premium valued on sales and book — a discount to its own history rather than a clear bargain versus peers.
Sign up to view all
ARES 12-Month Price Forecast
ARES presents a classic de-rated franchise debate: the stock has fallen 22.49% YTD with -33.11% relative strength versus the S&P 500, yet the analyst floor sits at the current price and the forward multiple of 18.48x is undemanding if the $9.36 EPS estimate holds. The problem is that reported results are moving the wrong way — revenue down 8.69% YoY, net margin compressed to 5.64% from 17.43%, and interest expense consuming roughly 69% of operating income — so the bull case depends on a fee-driven earnings normalization that has not yet appeared in GAAP numbers. The 5.0% dividend yield and 3.33x payout ratio add a coverage question that caps enthusiasm, while the $440.5 billion credit AUM exposure keeps the stock hostage to private credit headlines. I would upgrade to bullish if Q4 revenue growth turns positive and EPS recovers above $0.50 with no new sector credit event, and downgrade to bearish if revenue declines again or the stock breaks below the October low of $112.27.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ares Management's 12-month outlook, with a consensus price target around $146.55 and implied upside of +9.4% versus the current price.
Average Target
$146.55
20 analysts
Implied Upside
+9.4%
vs. current price
Analyst Count
20
covering this stock
Price Range
$129 - $171
Analyst target range
Coverage is robust, with 20 analysts and a distribution of 13 Buy, 7 Hold, and 0 Sell, yielding a consensus recommendation of "buy" (mean rating of 1.95 on a 1-to-5 scale where lower is more bullish). The average target price of $146.50 implies roughly +13.6% upside from the current $128.93, and notably the lowest target of $128.00 sits essentially at the current price — meaning even the most bearish analyst sees no downside from here. The consensus therefore leans clearly bullish, though the presence of seven Hold ratings and the recent cluster of reiterations rather than upgrades suggests conviction is moderate rather than emphatic.\n\nThe target range of $128.00 to $171.00 is moderately wide — the high target implies about +32.6% upside and would require multiple expansion back toward the stock's historical PS band alongside a recovery in realizations and fundraising momentum, while the low target of $128.00 essentially prices in a flat-to-modest outcome with continued margin and credit-quality pressure but no deterioration. Institutional activity in late October 2026 shows a wall of reiterations — TD Cowen (Buy), Barclays (Overweight), JP Morgan (Overweight), RBC (Outperform), Wells Fargo (Overweight), Keefe Bruyette (Market Perform), BMO (Market Perform), Piper Sandler (Overweight), and UBS (Neutral) — with no upgrades or downgrades, a pattern that signals analysts are holding fire pending clarity on private credit conditions and the next fundraising cycle. The absence of Sell ratings combined with the tight low-end anchor suggests downside is viewed as limited, but the lack of fresh upgrades caps near-term re-rating potential.
Drowning in data?
Find the real signal!
Bulls vs Bears: ARES Investment Factors
The bear case currently has stronger near-term evidence: revenue is down 8.69% YoY, net margin has compressed from 17.43% to 5.64%, EPS has fallen three consecutive quarters, and the stock is down 22.49% YTD with -33.11% relative strength versus the S&P 500. The bull case rests less on reported results than on valuation and positioning: an 18.48x forward PE, PS and P/B near multi-year lows, a 5.0% yield, zero Sell ratings, and an analyst low target of $128.00 that sits at the current price. The single most important tension is whether the $409.9 billion fee-earning AUM base keeps compounding fast enough to offset credit-quality fears and re-ignite realizations, because that is what would close the gap between the $0.015 trailing EPS and the $9.36 forward estimate. If fundraising and carry recover, the de-rated multiple re-rates quickly; if private credit headlines worsen, the 18.48x forward PE proves to be a value trap rather than a discount. On balance, the evidence favors a cautiously constructive stance, but conviction should be moderate given seven Hold ratings and no fresh upgrades.
Bullish
- Analyst floor sits at current price: The lowest of 20 analyst targets is $128.00 versus the $128.93 current price, meaning even the most bearish covering analyst models essentially zero downside. With 13 Buy, 7 Hold and 0 Sell ratings and a mean rating of 1.95, the consensus is clearly constructive, and the $146.50 average target implies +13.6% upside.
- Forward earnings multiple is undemanding: The forward PE of 18.48x on consensus EPS of $9.36 is modest in absolute terms and far below the 82.46x trailing multiple, which is distorted by a $0.015 trailing EPS. The market is effectively pricing a normalization of fee-related earnings that has not yet been reflected in GAAP results, leaving room for multiple support if estimates hold.
- Valuation near multi-year lows: PS has compressed to 5.43x from a historical band of roughly 10.2x (Q4 2021) to 36.1x (Q1 2024), and P/B has fallen from 15.07x in Q3 2024 to 8.22x today. The stock trades at just 38.7% of its 52-week range of $95.80–$181.19, so a substantial amount of private credit pessimism is already embedded in the price.
- Recurring fee base remains intact: Management fees of $1.039 billion anchor Q3 2026 revenue of $1.514 billion, supported by $409.9 billion of fee-earning AUM within $671.3 billion total AUM. The 8.69% YoY revenue decline reflects weaker realizations (carry of $263.0 million plus principal investment income of just $18.4 million) rather than erosion of the recurring fee engine.
Bearish
- Revenue is contracting year-over-year: Q3 2026 revenue of $1.514 billion fell 8.69% versus $1.658 billion in Q3 2025, following $1.429 billion in Q2 and $1.533 billion in Q1, a clear step-down from the $1.766 billion Q4 2025 run-rate. A negative growth print directly undermines the growth premium that alternative managers historically command.
- Net income and EPS are collapsing: Q3 2026 net income of $85.3 million (5.64% net margin) compares with $288.9 million (17.43% margin) a year earlier, and EPS has slid sequentially from $0.52 in Q1 to $0.49 in Q2 to $0.26 in Q3. A $123.5 million negative swing in other income/expense versus the prior year's +$302.9 million gain drove much of the damage, highlighting earnings volatility.
- Interest burden consumes operating profit: Interest expense of $250.7 million absorbed roughly 69% of Q3 2026 operating income of $365.1 million, and debt-to-equity stands at 3.49x. With a beta of 1.507 and a 45.87% max drawdown, the leverage profile amplifies both fundamental and market-driven downside.
- Dividend coverage is stretched: The 5.0% dividend yield comes with a 3.33x payout ratio, and Q2 2026 dividends paid of $513.8 million exceeded that quarter's operating cash flow, which was itself a -$351.4 million burn. TTM free cash flow of $836.1 million against a ~$52.5 billion market cap is only a ~1.6% FCF yield, leaving little cushion if realizations stay weak.
ARES Technical Analysis
ARES is in a recovery phase within a broader downtrend: the stock is down 17.09% over the past year and 22.49% year-to-date, a stark underperformance versus the S&P 500's +10.39% 1-year and +10.62% YTD returns (relative strength of -27.48% and -33.11%, respectively). At $128.93, the shares sit at roughly 38.7% of the 52-week range of $95.80–$181.19 — closer to the low than the high, but well off the bottom, implying the market has already priced a meaningful amount of bad news while still withholding a full re-rating. The 45.87% max drawdown underscores how severe the de-rating has been for a large-cap alternative manager.\n\nShort-term momentum has turned decisively positive and is diverging from the longer-term trend: the stock is up 9.68% over the past month versus a -1.99% decline for SPY, producing a relative strength of +11.67% — the strongest reading across any horizon in the dataset. That one-month surge follows a -7.76% three-month change and a +4.69% six-month change, a pattern consistent with a sharp August rally (from ~$128 on July 31 to $149.45 on August 13), a September-October fade to $112.27 on October 16, and then a fresh rebound to $132.96 by November 2 before the -3.03% pullback to $128.93 on November 3. The 1-month/1-year divergence — positive near-term against a deeply negative annual trend — most plausibly signals mean reversion off an oversold base rather than a confirmed trend reversal, particularly given the single-day -3.03% reversal on elevated volume of 1.85 million shares.\n\nKey technical levels are well defined: support sits at the 52-week low of $95.80 (roughly 26% below the current price), with a nearer-term floor around the October swing low of $112.27, while resistance is anchored at the 52-week high of $181.19 (about 40.5% above current levels) and, more immediately, the August high of $149.45. A breakout above $149.45 would suggest the market is willing to re-rate the private credit narrative, whereas a breakdown below $112 would confirm the downtrend and likely retest the $95.80 low. With a beta of 1.507, ARES is roughly 50% more volatile than the market, meaning position sizing should assume amplified drawdowns — the 45.87% max drawdown is a realistic stress-case reference, and the 6.62 short ratio indicates short sellers are not aggressively pressing the name despite the weak tape.
Beta
1.51
1.51x market volatility
Max Drawdown
-45.9%
Largest decline past year
52-Week Range
$96-$181
Price range past year
Annual Return
-11.4%
Cumulative gain past year
| Period | ARES Return | S&P 500 |
|---|---|---|
| 1m | +15.7% | -5.0% |
| 3m | -2.1% | -4.9% |
| 6m | +6.1% | -0.5% |
| 1y | -11.4% | +9.6% |
| ytd | -19.4% | +7.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARES Fundamental Analysis
The revenue trajectory is decelerating and uneven: Q3 2026 revenue of $1.514 billion declined 8.69% year-over-year against $1.658 billion in Q3 2025, following $1.429 billion in Q2 2026 and $1.533 billion in Q1 2026, versus $1.766 billion in Q4 2025 — a clear step-down from the prior year's run-rate. Segment data shows the engine is management fees at $1.039 billion, supplemented by carried interest of $263.0 million, administrative service revenue of $118.5 million, management service incentive fees of $42.8 million, and principal investment income of just $18.4 million — meaning performance-related revenue (carry plus principal investment) is a comparatively small and volatile slice, and the YoY decline likely reflects weaker realizations rather than a collapse in the recurring fee base. For the investment case, the durability of the $409.9 billion fee-earning AUM base matters more than any single quarter's realization timing, but the negative growth print explains why the market has questioned the growth premium.\n\nProfitability remains positive but is compressing at the bottom line: Q3 2026 net income was $85.3 million (a 5.64% net margin) on $1.514 billion of revenue, down sharply from $288.9 million (17.43% margin) in Q3 2025, while gross margin improved to 79.49% from 60.19% a year earlier — a divergence that points to higher operating costs and interest burden rather than gross-level deterioration. Operating income of $365.1 million (24.12% operating margin) was actually up from $349.4 million a year ago, but interest expense of $250.7 million consumed roughly 69% of operating income, and a $123.5 million negative swing in other income/expense versus the prior year's +$302.9 million gain drove the net income decline. The sequential trend is also soft — EPS fell from $0.52 in Q1 to $0.49 in Q2 to $0.26 in Q3 — and the trailing EPS of $0.015 versus a forward estimate of $9.36 highlights how distorted GAAP results are by mark-to-market and non-cash items relative to the fee-based earnings power analysts are underwriting.\n\nThe balance sheet carries meaningful leverage typical of the alternative-manager model: debt-to-equity of 3.49x, a current ratio of 2.24, and TTM free cash flow of $836.1 million against a $52.5 billion market cap (an FCF yield of roughly 1.6%). Cash flow is highly lumpy — Q1 2026 generated +$406.5 million in operating cash flow, Q2 2026 burned -$351.4 million, and Q4 2025 burned -$483.7 million — reflecting the working-capital and realization timing inherent to the business, while dividends paid of $513.8 million in Q2 alone exceeded that quarter's operating cash flow. ROE of 12.33% is respectable but not exceptional for the sector, and the 3.33x payout ratio signals distributions are being funded partly from balance-sheet capacity rather than pure current earnings; the 5.0% dividend yield is attractive but should be underwritten against that coverage gap.
Quarterly Revenue
$1.5B
2026-09
Revenue YoY Growth
-8.7%
YoY Comparison
Gross Margin
79.5%
Latest Quarter
Free Cash Flow
$836147000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARES Overvalued?
Because trailing net income is positive but negligible (EPS of $0.015), the trailing PE of 82.46x is economically meaningless and I have selected the forward PE of 18.48x as the primary metric, corroborated by the 5.43x price-to-sales and 9.73x EV/sales ratios. The enormous gap between the 82.46x trailing and 18.48x forward multiple implies the market expects a dramatic earnings inflection — consistent with the $9.36 consensus forward EPS versus $0.015 trailing — which is a high-conviction bet on fee-related earnings normalization and realization recovery. The 28.68x EV/EBITDA and 8.22x price-to-book further confirm this is priced as a scaled, capital-light-ish franchise rather than a distressed asset manager.\n\nAgainst the asset management industry, the picture is mixed: a 5.43x PS ratio and 8.22x P/B sit at the high end for traditional managers but are defensible for a scaled alternatives platform with 74.79% gross margins and 27.22% operating margins, while the 18.48x forward PE is not demanding in absolute terms. The negative PEG ratio of -15.52 is a mechanical artifact of the trailing earnings base and should be disregarded; the more telling signal is the 5.0% dividend yield, which is unusually high for a growth-oriented alternatives manager and suggests the market is pricing in elevated risk rather than paying for growth. On balance, the stock screens as modestly discounted on forward earnings but premium on sales and book — a classic disagreement between earnings-based and asset-based valuation frameworks.\n\nHistorically, ARES has traded at far richer multiples: the PS ratio has ranged from roughly 10.2x (Q4 2021) to 36.1x (Q1 2024) and stood at 17.46x as of Q3 2026, while P/B has compressed from 15.07x in Q3 2024 to 8.22x today and the PE ratio has swung from 26.7x (Q4 2022) to 694x (Q1 2025) on earnings volatility. The current 5.43x PS and 8.22x P/B are near the low end of the multi-year band, implying the market has already de-rated the franchise substantially — which could represent a value opportunity if fee growth resumes, or reflect genuine fundamental deterioration if private credit stress persists. Given the 22.49% YTD decline and the stock trading at 38.7% of its 52-week range, the valuation now embeds considerable skepticism rather than optimism.
PE
82.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 27x~112x
vs. Industry Avg
16.6x
Industry PE ~16.6x*
EV/EBITDA
28.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and leverage. Q3 2026 revenue fell 8.69% YoY to $1.514 billion while net income dropped to $85.3 million from $288.9 million, and EPS declined sequentially from $0.52 to $0.49 to $0.26, showing that results hinge on volatile performance fees and mark-to-market swings rather than the recurring fee base. Interest expense of $250.7 million consumed roughly 69% of operating income, debt-to-equity is 3.49x, and the 3.33x payout ratio means the 5.0% dividend is not fully covered by current earnings, with Q2 dividends of $513.8 million exceeding that quarter's operating cash flow. Cash flow is highly lumpy — +$406.5 million in Q1 2026, -$351.4 million in Q2, and -$483.7 million in Q4 2025 — so any sustained slowdown in realizations would pressure both distributions and the balance sheet.
Market and competitive risks are dominated by the private credit narrative and valuation sensitivity. Credit strategies account for $440.5 billion of $671.3 billion total AUM, making ARES the most direct listed proxy for a theme that has already produced Blue Owl's April redemption cap and a $1.4 billion fund liquidation in February, both of which triggered sector-wide selloffs. The stock's beta of 1.507 means it amplifies market moves by roughly 50%, and its -27.48% one-year relative strength versus the S&P 500's +10.39% shows how violently sentiment has swung. Valuation is mixed — 5.43x PS and 8.22x P/B are near multi-year lows, but 28.68x EV/EBITDA and 9.73x EV/sales still embed a premium franchise assumption, so further multiple compression is possible if fee growth stalls.
In a worst-case scenario, persistent private credit stress forces further redemption gates or fund liquidations across the sector, fundraising slows, carry realizations stay depressed, and the forward EPS estimate of $9.36 proves unreachable, causing analysts to cut targets and the multiple to compress toward the low end of its historical band. The realistic downside reference is the 52-week low of $95.80, roughly -25.7% from the current $128.93, with the October swing low of $112.27 (-12.9%) as the first stop; the 45.87% max drawdown shows how far the stock can fall in a genuine stress episode. In that scenario an investor could lose roughly a quarter of capital to the 52-week low and materially more in a repeat of the maximum drawdown.
FAQ
Ranked by severity, the first is private credit concentration: credit strategies are $440.5 billion of $671.3 billion total AUM, and Blue Owl's April redemption cap plus a $1.4 billion fund liquidation in February triggered sector-wide selling that hit alternative managers and banks together — ARES is the most direct listed proxy for that theme. Second is earnings quality and leverage: interest expense of $250.7 million consumed roughly 69% of Q3 2026 operating income of $365.1 million, debt-to-equity is 3.49x, and EPS has fallen three straight quarters, so the $9.36 forward estimate is doing heavy lifting. Third is dividend coverage, with a 3.33x payout ratio and Q2 dividends of $513.8 million exceeding that quarter's operating cash flow, meaning the 5.0% yield is not fully covered by current earnings. Fourth is market sensitivity: a beta of 1.507 amplifies drawdowns, and the stock has already demonstrated a 45.87% max drawdown and -27.48% one-year relative strength versus the S&P 500's +10.39%.
The scenario framework assigns 55% to a base case of $140–$150, 25% to a bull case of $160–$171, and 20% to a bear case of $96–$112. The base case is most likely: fee-related earnings grind higher on the $1.039 billion quarterly management fee base, revenue stabilizes near the $1.5 billion run-rate, realizations stay muted, and the stock drifts toward the $146.50 analyst average target (+13.6%) as private credit headlines fade without a full sentiment recovery. The bull case requires a genuine catalyst — Q4 revenue growth turning positive with EPS above $0.50, a new flagship credit fund close pushing fee-earning AUM materially above $409.9 billion, and carry recovering from the depressed $263.0 million Q3 level — to drive a re-rating toward the $171.00 high target. The bear case is triggered by another redemption gate or fund liquidation, revenue declining again YoY, and estimate cuts that compress the multiple toward the $95.80 52-week low. The key assumption across all three is whether the $9.36 forward EPS estimate holds.
The answer depends on the metric, and that disagreement is the heart of the debate. On forward earnings the stock looks modestly undervalued: 18.48x forward PE on $9.36 consensus EPS is undemanding in absolute terms and far below the 82.46x trailing multiple, which is distorted by trailing EPS of just $0.015. On sales and book it looks closer to fair-to-premium: 5.43x PS and 8.22x P/B are near the low end of the historical band (PS ranged roughly 10.2x in Q4 2021 to 36.1x in Q1 2024; P/B was 15.07x in Q3 2024) but still high relative to traditional asset managers, and 28.68x EV/EBITDA embeds a premium franchise assumption. The market is therefore paying a discount to ARES's own history while still paying up versus the broader industry — implying investors expect fee-related earnings normalization but are unwilling to underwrite a full recovery until private credit sentiment stabilizes. At 38.7% of the 52-week range, the price already embeds substantial pessimism, so the risk is less about overpaying than about whether the forward estimate is real.
From a risk/reward standpoint the setup is asymmetric but not clean: the analyst low target of $128.00 sits essentially at the $128.93 current price, implying the Street models no downside, while the $146.50 average target offers +13.6% upside and the $171.00 high target implies +32.6%. Against that, the realistic bear case runs to the October low of $112.27 (-12.9%) and the 52-week low of $95.80 (-25.7%), so the reward-to-risk is roughly 1:1 to 1:2 depending on which downside anchor is used. The fundamental caveat is that revenue fell 8.69% YoY to $1.514 billion and EPS slid from $0.52 to $0.49 to $0.26 across 2026, so the 18.48x forward PE depends on a $9.36 EPS estimate that has not yet appeared in GAAP results. It is a reasonable buy for long-horizon investors comfortable with private credit headline risk who want a 5.0% yield and a de-rated franchise at 5.43x sales, but it is not a low-volatility entry — a beta of 1.507 and a 45.87% max drawdown argue for staged accumulation rather than a full position at current levels.
ARES is structurally a long-term holding but tactically a difficult short-term trade. The business model — recurring management fees on $409.9 billion of fee-earning AUM, 74.79% gross margins, and a 5.0% dividend yield — rewards multi-year compounding, and the current 5.43x PS and 8.22x P/B sit near multi-year lows, which is the kind of entry that historically favors patient capital. However, the near-term tape is volatile: a beta of 1.507, a 45.87% max drawdown, a -3.03% single-day reversal on 1.85 million shares, and a 9.68% one-month rebound against a -17.09% one-year decline all point to headline-driven swings rather than a smooth trend. Earnings visibility is also low because GAAP results are dominated by mark-to-market and realization timing — EPS moved from $0.52 to $0.49 to $0.26 in three quarters. A minimum holding period of 18–24 months is appropriate to let the fee base compound and to ride out a private credit sentiment cycle, with position sizing that assumes a 25%+ drawdown is possible.

